Viral Vector Commercialization – Part 1: Technology Transfer Processes

Advancement in the ability for viral vectors to efficiently deliver genetic material to target cells is demonstrating the potential of gene therapies and vaccines to revolutionize medicine and driving demand for viral vector-mediated therapies. However, developing and manufacturing viral vectors at scale require scientific expertise, technological know-how, and a solid infrastructure.

A successful, efficient technology transfer process is critical for progressing gene therapy products toward commercialization. Learn more about the tech transfer strategies that help companies stay up-to-date on the latest advancements in the field and accelerate the development and commercialization of upcoming gene therapies and vaccines.